# Sermorelin Telehealth — Frequently Asked Questions > Plain-English answers to the questions readers most often bring to the sermorelin literature: mechanism, GH-replacement comparison, IGF-1 monitoring, the 503A compounding pathway, the WADA prohibition, and what the 2024-2025 research says. Answers to the questions readers most often bring to the sermorelin literature — mechanism, monitoring, regulatory context, and what the recent research says. Direct answers, with citations. ## What is sermorelin and how does it work? Sermorelin is the synthetic acetate of the first twenty-nine amino acids of human growth hormone-releasing hormone — the N-terminal active fragment of the natural 44-residue hypothalamic peptide. It binds the GHRH receptor on anterior-pituitary somatotrophs and triggers a brief, physiologic pulse of endogenous growth hormone through a Gαs / cAMP / PKA / CREB cascade [1]. The pulse is self-limiting because intact somatostatin tone and rising IGF-1 negative feedback both close the loop — the pituitary does not fire indefinitely with escalating dose [20]. Half-life is approximately eleven to twelve minutes [6], so a single subcutaneous dose produces a single discrete physiologic pulse rather than sustained receptor occupancy. ## How is sermorelin different from injectable growth hormone (rhGH)? Recombinant human growth hormone is the hormone itself, injected exogenously, producing sustained receptor occupancy that bypasses the pituitary's intrinsic negative-feedback brakes. Sermorelin is upstream of those brakes — it triggers the patient's own pituitary to fire endogenous GH pulses, which remain self-limiting under normal somatostatin and IGF-1 feedback [20]. The pharmacologic ceiling is the most-cited mechanistic argument for the GHRH-agonist class in the adult-research literature: GH release is pulsatile and physiologic rather than continuous and supraphysiologic, which is argued to reduce the risk of edema, glucose dysregulation, and supraphysiologic IGF-1 elevation seen with chronic rhGH administration [20]. The empirical comparison between long-term sermorelin and long-term rhGH in healthy adults has not been formally trialed; the mechanistic argument is theoretical even if it is structurally well-grounded. ## What lab tests are tracked during sermorelin research and clinical monitoring? Serum IGF-1 is the principal blood biomarker [12]. IGF-1 has a longer half-life than GH itself and integrates the pulsatile GH signal over hours to days, which makes it the practical biomarker for outpatient monitoring. The standard adult panel that travels with IGF-1 typically includes IGFBP-3, fasting glucose, hemoglobin A1c, fasting insulin and HOMA-IR, the comprehensive lipid panel, thyroid-stimulating hormone with free T4, and a baseline cancer-screening history [12]. Research protocols typically check IGF-1 at four to eight weeks following initiation and every three to six months thereafter, targeting the upper-quartile age-matched reference range rather than supraphysiologic values [12]. The metabolic-panel labs travel with IGF-1 because of the documented inverse relationship between peak GH response and HOMA-IR in obese subjects [7]. ## What does the research say about body composition, cognition, and sleep? On body composition, the most direct placebo-controlled evidence in the GHRH-receptor agonist class comes from tesamorelin — fifteen to eighteen percent reduction in visceral adipose tissue versus placebo over twenty-six weeks in HIV-associated lipodystrophy [15]. The sermorelin-specific adult-somatopause data (Khorram 1997) showed approximately 1.26 kilograms of lean-mass gain in men over sixteen weeks with a closely related GHRH(1-29) analog [3]. On cognition, the Baker 2012 trial of tesamorelin showed significant improvement in executive function (p = .005) over twenty weeks in older adults [4], with magnetic-resonance spectroscopy demonstrating increased GABA and decreased myo-inositol as a neurochemical signature [5]. The Vitiello 2006 trial of GHRH(1-29) over six months had earlier shown executive-function gains [16]. On sleep, sermorelin's eleven-to-twelve-minute half-life [6] is engineered to coincide with the slow-wave-sleep GH pulses that dominate the first third of the night — this is the basis for the conventional nightly-bedtime dose timing across the literature. Direct polysomnographic evidence of sleep-architecture changes under sermorelin is more limited than the body-composition and cognitive evidence. ## What's the half-life of sermorelin and why is bedtime dosing the convention? Plasma half-life is approximately eleven to twelve minutes following intravenous or subcutaneous administration, with plasma clearance of 2.4 to 2.8 liters per minute [6]. The short half-life is by design — each subcutaneous dose produces one discrete physiologic GH pulse rather than continuous receptor occupancy. Rapid clearance is driven principally by dipeptidyl peptidase IV cleavage of the N-terminal Tyr-Ala dipeptide [6]. Bedtime dosing is conventional because endogenous GH is sleep-coupled — the largest physiologic GH pulses occur during slow-wave sleep, which consolidates during the first third of the night [4]. A sermorelin dose timed to bedtime is engineered to reinforce a pulse the body would have fired anyway. ## Why is compounded sermorelin available in the U.S. if no FDA-approved finished product exists? The Geref new drug application (NDA 020443, Serono Laboratories) was approved in 1997 for pediatric idiopathic GHD and provocative pituitary diagnostic testing [1]. The manufacturer voluntarily discontinued Geref in 2008 for commercial and manufacturing-process reasons. The FDA's March 4, 2013 Federal Register determination (78 FR 14114) expressly confirmed that the withdrawal was not for reasons of safety or effectiveness [18]. That regulatory finding is the legal predicate for ongoing compounding under the 'previously approved, not for safety' enforcement-discretion pathway. Sermorelin available to U.S. patients in 2026 is prepared by 503A pharmacies (patient-specific prescriptions) and 503B outsourcing facilities (sterile bulk for healthcare facilities), under valid prescriptions [12]. This site does not dispense any product and is not affiliated with any compounding pharmacy. ## What are the documented adverse effects of sermorelin in published trials? In the FDA-approved Geref pediatric registration data, the most common treatment-emergent adverse event was a transient injection-site reaction (pain, swelling, or redness) in approximately one in six patients [8]. Headache, flushing, dysphagia, dizziness, hyperactivity, somnolence, and urticaria each occurred at rates below one percent. No clinically significant changes in serum chemistries, thyroid function, or glucose tolerance were observed over the trial period [8]. The adult somatopause trials (Corpas 1992, Khorram 1997) and the cognitive trials did not report significant adverse signals beyond transient injection-site reactions and occasional flushing [2][3][4]. These trials were short (two to twenty-four weeks) and small relative to a multi-year safety study; the long-term adult safety record is therefore limited. ## What is the research basis for combining sermorelin with ipamorelin? Sermorelin is a GHRH-receptor agonist; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. The two compounds act through independent receptors that converge on the same somatotroph cell. A 2020 review of growth-hormone secretagogues consolidated the mechanistic case that combined GHRH-R and GHS-R stimulation produces synergistic GH release greater than the sum of either pathway alone [14]. This is the pharmacologic basis for the most widely compounded GHRH-secretagogue blend in the adult-research and telehealth literature. The combination is mechanistically rational; specific large-scale clinical efficacy data for the precise sermorelin-ipamorelin blend in healthy adults is more limited than the underlying receptor-pharmacology argument. ## Is sermorelin prohibited under WADA rules? Yes. Sermorelin and all GHRH-class peptides are prohibited under the World Anti-Doping Agency's Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — at all times, both in-competition and out-of-competition, for athletes subject to WADA testing. Tested athletes who use sermorelin face standard anti-doping sanctions. This is a relevant disclosure for any competitive athlete reading the research literature; it does not affect the regulatory status of the compound for non-athlete adult use. ## How does the 2024-2025 research characterize the GHRH axis beyond growth hormone? The recent review literature has reframed the GHRH receptor as a broader endocrine and regenerative target than the original pituitary-GH-release framing implied. A 2025 review by Dulce, Hare and colleagues catalogued GHRH-class cardioprotection in preclinical models — restored phospholamban phosphorylation, improved diastolic function, attenuated post-MI hypertrophy [9]. A 2024 review by Steenblock and Bornstein characterized the axis as a therapeutic target in diabetes and metabolism, with GHRH agonists enhancing pancreatic beta-cell survival in vitro and in animal models [10]. A 2024 consolidation by Andrew Schally and colleagues summarized the expanding clinical scope across cardiac repair, beta-cell survival, fibroblast-mediated wound healing, neuroprotection in stroke and SMA models, and antitumor activity for GHRH antagonists [11]. Most of this evidence remains preclinical for the non-pituitary indications; the clinical translation is ahead of where the reviews reach. ## Is sermorelin different from CJC-1295 or Modified GRF (1-29)? Yes, mechanistically related and structurally close. CJC-1295 without DAC and Modified GRF (1-29) are sermorelin's twenty-nine-amino-acid sequence with four amino-acid substitutions — D-alanine at position two (the critical one — it blocks dipeptidyl peptidase IV cleavage), glutamine at position eight, alanine at position fifteen, and leucine at position twenty-seven [14]. Same GHRH receptor, same downstream pharmacology, longer functional half-life (approximately thirty minutes rather than sermorelin's eleven to twelve [6][14]). The longer signaling window is sometimes preferred where extended GHRH stimulation is the design intent; sermorelin remains preferred where strict physiologic pulsatility is the goal. ## Is sermorelin the same as tesamorelin? No — closely related, mechanistically of the same class, but structurally and regulatorily distinct. Tesamorelin (Egrifta, Theratechnologies) is a stabilized GHRH analog FDA-approved in 2010 for HIV-associated lipodystrophy, and is the only currently FDA-approved finished member of the GHRH-receptor agonist class on the U.S. market [15]. Tesamorelin shares sermorelin's GHRH-receptor mechanism but has a longer effective half-life. Tesamorelin was the GHRH-class proxy in the Baker 2012 cognitive trial and the Friedman 2013 MRS study [4][5], which is why those trials are commonly read into the broader sermorelin literature. ## Why are telehealth practices delivering sermorelin if no finished FDA product exists? Because the 503A and 503B pharmacy-compounding pathway expressly accommodates previously-approved drugs that were not withdrawn for safety or efficacy reasons, and sermorelin sits squarely in that category per the 2013 Federal Register determination [18]. The telemedicine consultation model became broadly viable for prescription-by-video after 2020, and the consultation-plus-compounded-prescription pattern is the operational model under which adult sermorelin is currently delivered in the United States [12]. The 2024 European review of adult GHD practice noted that the post-2008 worldwide unavailability of pharmaceutical GHRH has materially changed how the adult GH/IGF-1 axis is investigated and treated [12]. This site reads that landscape; it does not operate within it as a provider. ## What does the site mean by 'editorial' rather than 'medical'? The site is a reading of the published literature. It is not a clinic, does not employ clinicians, does not provide medical advice, does not prescribe, does not dispense, and is not affiliated with any compounding pharmacy or telemedicine provider. The 'telehealth' in the domain name is editorial framing — a description of the regulatory and delivery context within which the literature is currently read in 2026 — rather than a claim about the site's services. Any reader considering sermorelin should consult an appropriately licensed clinician who can review the reader's individual medical history, contraindications, and laboratory results. ## References [I] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Pescovitz O, Heinrich JJ, Reiter EO, et al. (Geref International Study Group). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology & Metabolism. 1996;81(3):1189-1196. PMID 8772599 · DOI 10.1210/jcem.81.3.8772599 · https://pubmed.ncbi.nlm.nih.gov/8772599/ [II] Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism. 1992;75(2):530-535. PMID 1379256 · DOI 10.1210/jcem.75.2.1379256 · https://pubmed.ncbi.nlm.nih.gov/1379256/ [III] Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. PMID 9141537 · DOI 10.1210/jcem.82.5.3943 · https://academic.oup.com/jcem/article-abstract/82/5/1472/2823341 [IV] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 2012;69(11):1420-1429. PMID 22869065 · DOI 10.1001/archneurol.2012.1970 · https://pmc.ncbi.nlm.nih.gov/articles/PMC3764914/ [V] Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV. Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology. 2013;70(7):883-890. PMID 23689947 · DOI 10.1001/jamaneurol.2013.1425 · https://jamanetwork.com/journals/jamaneurology/fullarticle/1696089 [VI] Serono Laboratories. GEREF (sermorelin acetate) injection — FDA-approved prescribing information. FDA Drug Label / NDA 020443. 1997. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443 [VII] Cordido F, Garcia-Buela J, Sangiao-Alvarellos S, Martinez T, Vidal O. The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors. Mediators of Inflammation. 2010;2010:434562. PMID 20150954 · DOI 10.1155/2010/434562 · https://pmc.ncbi.nlm.nih.gov/articles/PMC2817384/ [VIII] Serono Laboratories. Sermorelin acetate prescribing information / drug monograph. FDA-approved label, summarized in RxList monograph. 1997. https://www.rxlist.com/sermorelin-acetate-drug.htm [IX] Dulce RA, Hatzistergos KE, Kanashiro-Takeuchi RM, Takeuchi LM, Balkan W, Hare JM. Growth hormone-releasing hormone signaling and manifestations within the cardiovascular system. Reviews in Endocrine and Metabolic Disorders. 2025. PMID 39883351 · DOI 10.1007/s11154-024-09939-0 · https://link.springer.com/article/10.1007/s11154-024-09939-0 [X] Steenblock C, Bornstein SR. GHRH in diabetes and metabolism. Reviews in Endocrine and Metabolic Disorders. 2024. PMID 39560873 · DOI 10.1007/s11154-024-09930-9 · https://pmc.ncbi.nlm.nih.gov/articles/PMC12137473/ [XI] Schally AV, Cai R, Zhang X, Sha W, Wangpaichitr M. The development of growth hormone-releasing hormone analogs: therapeutic advances in cancer, regenerative medicine, and metabolic disorders. Reviews in Endocrine and Metabolic Disorders. 2024. PMID 39592529 · DOI 10.1007/s11154-024-09929-2 · https://pmc.ncbi.nlm.nih.gov/articles/PMC12137413/ [XII] Caputo M, Mele C, Ferrero A, Leone I, Daffara T, Marzullo P, Prodam F, Aimaretti G. A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to real life. Journal of Clinical Medicine. 2024;13(20):6079. PMID 39458029 · DOI 10.3390/jcm13206079 · https://www.mdpi.com/2077-0383/13/20/6079 [XIV] Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. DOI 10.1002/rco2.9 · https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 [XV] Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. PMID 18057338 · DOI 10.1056/NEJMoa072375 · https://www.nejm.org/doi/full/10.1056/NEJMoa072375 [XVI] Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone-releasing hormone improves the cognition of healthy older adults. Neurobiology of Aging. 2006;27(2):318-323. PMID 16399218 · DOI 10.1016/j.neurobiolaging.2005.01.010 · https://pubmed.ncbi.nlm.nih.gov/16399218/ [XVIII] U.S. Food and Drug Administration. Determination that GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013;78 FR 14114. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams [XX] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308. PMID 18046908 · DOI 10.2147/ciia.2006.1.4.307 · https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/ --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.